A Randomized, Double-Blind, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler and Open-Label Symbicort Turbuhaler in Participants with Inadequately Controlled Asthma (VATHOS)
Latest Information Update: 08 Dec 2024
Price :
$35 *
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms VATHOS
- Sponsors AstraZeneca; AstraZeneca AB
- 09 Sep 2024 Planned End Date changed from 24 Mar 2025 to 28 Feb 2025.
- 09 Sep 2024 Planned primary completion date changed from 24 Mar 2025 to 28 Feb 2025.
- 09 Sep 2024 Status changed from recruiting to active, no longer recruiting.